JPH06321752A - Skin beautifying agent - Google Patents
Skin beautifying agentInfo
- Publication number
- JPH06321752A JPH06321752A JP10672793A JP10672793A JPH06321752A JP H06321752 A JPH06321752 A JP H06321752A JP 10672793 A JP10672793 A JP 10672793A JP 10672793 A JP10672793 A JP 10672793A JP H06321752 A JPH06321752 A JP H06321752A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- compound
- formula
- effect
- skin cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 17
- 229930012930 isoflavone derivative Natural products 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 3
- 230000002087 whitening effect Effects 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 9
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000019612 pigmentation Effects 0.000 abstract description 7
- 239000006210 lotion Substances 0.000 abstract description 6
- 206010014970 Ephelides Diseases 0.000 abstract description 4
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 206010042496 Sunburn Diseases 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 4
- 238000012258 culturing Methods 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 230000003061 melanogenesis Effects 0.000 abstract 1
- 241001446247 uncultured actinomycete Species 0.000 abstract 1
- -1 inositol phospholipid Chemical class 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 230000008099 melanin synthesis Effects 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 210000002752 melanocyte Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 239000002304 perfume Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 4
- 229950000329 thiouracil Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- VDBJCDWTNCKRTF-UHFFFAOYSA-N 6'-hydroxyspiro[2-benzofuran-3,9'-9ah-xanthene]-1,3'-dione Chemical compound O1C(=O)C2=CC=CC=C2C21C1C=CC(=O)C=C1OC1=CC(O)=CC=C21 VDBJCDWTNCKRTF-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical class OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は美白剤及び皮膚化粧料に
関し、更に詳細にはメラノサイトにおけるメラニン生成
を抑制し、紫外線照射後の皮膚の美白効果に優れ、日焼
け等によるシミ及びソバカス等を予防及び治療すること
のできる皮膚化粧料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening agent and a skin cosmetic, and more specifically, it suppresses the formation of melanin in melanocytes, has an excellent whitening effect on the skin after UV irradiation, and prevents spots and freckles due to sunburn etc. And skin care products that can be treated.
【0002】[0002]
【従来の技術】シミ、ソバカス及び日焼け後の肌への色
素沈着は、加齢に伴い発生、増加、或いは消失しにくく
なり、中高年齢層にとって悩みとなっている。これらの
色素沈着症の発症機構は未だ明確にはされていないが、
太陽光線、特に紫外線や、メラノサイト刺激ホルモンな
どの作用により、表皮メラノサイトでのメラニン合成機
構が亢進したためと考えられている。また、表皮角化細
胞(ケラチノサイト)の加齢に伴う角化遅延も、表皮内
のメラニン顆粒密度の増加、即ち臨床的に色素沈着が増
加する症状を発現させるものと考えられる。これらの色
素沈着部は局部的に存在し、周囲の正常皮膚色と明らか
な差異が生ずることもある。2. Description of the Related Art Pigments, freckles, and pigmentation on the skin after sunburn are less likely to occur, increase, or disappear with age, which is a problem for middle-aged and older people. Although the pathogenic mechanism of these pigmentation diseases has not been clarified yet,
It is considered that the mechanism of melanin synthesis in epidermal melanocytes was enhanced by the action of sunlight, especially ultraviolet rays, and melanocyte-stimulating hormone. Moreover, it is considered that the delay in keratinization of epidermal keratinocytes (keratinocytes) with aging also causes an increase in the density of melanin granules in the epidermis, that is, a clinically symptomatic increase in pigmentation. These pigmented areas are localized and may be distinctly different from the surrounding normal skin color.
【0003】このような後天的色素(即ちメラニン)沈
着部を正常皮膚色にまで回復可能な薬剤の開発が強く望
まれており、これまでに多くの薬剤が商品化されてきて
いる。例えば近年、優れた還元能を有するビタミンC
(L−アスコルビン酸)誘導体を配合した化粧料も用い
られてきた。しかしながら、これも安定性に難があると
ともに、外用では効果がほとんど認められない。一方欧
米に於いて、ハイドロキノンにシミの治療効果や黒人の
皮膚を白くする効果があることが知られているが、これ
らも物質自体の安全性(刺激性、アレルギー性)に問題
があり、また白斑を生じさせるケースもあるなどの点か
ら薬剤として配合することには問題がある。その他にも
種々の成分、例えばイソフラボン誘導体(特開昭58−
225004号公報)や、桂皮酸誘導体としてのp−ヒ
ドロキシ桂皮酸誘導体(特開昭59−196813号公
報)等がメラニン抑制剤として知られている。There is a strong demand for the development of a drug capable of recovering such an acquired pigment (ie, melanin) deposit to a normal skin color, and many drugs have been commercialized so far. For example, in recent years, vitamin C has an excellent reducing ability.
Cosmetics containing a (L-ascorbic acid) derivative have also been used. However, this also has a difficulty in stability, and almost no effect is observed for external use. On the other hand, in Europe and America, it is known that hydroquinone has a therapeutic effect on spots and an effect to whiten black skin, but these also have problems in safety of the substance itself (irritation, allergenicity), and Compounding as a drug is problematic in that it may cause vitiligo in some cases. In addition, various components such as isoflavone derivatives (Japanese Patent Laid-Open No. 58-58
225004) and p-hydroxycinnamic acid derivatives as cinnamic acid derivatives (JP-A-59-196813) are known as melanin inhibitors.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、未だ充
分な色素沈着予防・改善効果と化粧品基剤への配合性と
を有する物質は知られていないのが現状である。従って
本発明の目的は優れた美白作用を有し、かつ化粧品とし
て有用な成分及びそれを含有する皮膚化粧料を提供する
ことにある。However, at present, no substance is known that has a sufficient pigmentation preventing / ameliorating effect and compoundability with a cosmetic base. Therefore, an object of the present invention is to provide a component having an excellent whitening effect and useful as a cosmetic, and a skin cosmetic containing the same.
【0005】[0005]
【課題を解決するための手段】そこで本発明者らは、メ
ラニン生成機構の研究を通して、メラノサイトにおける
メラニン生成を抑制し、紫外線などの外部刺激に基づく
色素沈着を減少又は消失させる物質を得るべく鋭意検討
した結果、下記一般式(1)で表わされるイソフラボン
誘導体が優れた色素沈着の予防・改善効果を有し、これ
を配合すれば良好な皮膚化粧料が得られることを見出
し、本発明を完成するに至った。[Means for Solving the Problems] Therefore, the inventors of the present invention have earnestly sought to obtain a substance that suppresses melanin production in melanocytes and reduces or eliminates pigmentation due to external stimuli such as ultraviolet rays through the study of melanin production mechanism. As a result of investigation, it was found that the isoflavone derivative represented by the following general formula (1) has an excellent pigmentation preventing / ameliorating effect, and that a good skin cosmetic can be obtained by blending this, and the present invention was completed. Came to do.
【0006】即ち、本発明は次の一般式(1)That is, the present invention has the following general formula (1):
【0007】[0007]
【化2】 [Chemical 2]
【0008】〔式中、R1 は水素原子又はメトキシ基
を、R2 は水素原子又は水酸基を示す〕で表わされるイ
ソフラボン誘導体からなる美白剤を提供するものであ
る。The present invention provides a whitening agent comprising an isoflavone derivative represented by the formula: wherein R 1 represents a hydrogen atom or a methoxy group, and R 2 represents a hydrogen atom or a hydroxyl group.
【0009】また、本発明は上記イソフラボン誘導体を
含有する皮膚化粧料を提供するものである。The present invention also provides a skin cosmetic containing the above isoflavone derivative.
【0010】本発明の皮膚化粧料の有効成分である化合
物(1)は、イノシトールリン脂質代謝回転阻害作用を
有することは知られている〔Imoto,M.et a
l,FEBS Lett.230,43〜46(198
8)、Nishioka,H.et al,J.Ant
ibiot.42:823〜825(1989)〕が、
当該化合物の皮膚に及ぼす作用については全く知られて
いない。この化合物(1)は上記文献に従い、放線菌を
培養することで得られる。Compound (1), which is an active ingredient of the skin cosmetics of the present invention, is known to have an inhibitory action on inositol phospholipid turnover [Imoto, M. et al. et a
1, FEBS Lett. 230, 43-46 (198
8), Nishioka, H .; et al, J .; Ant
ibiot. 42 : 823-825 (1989)],
Nothing is known about the effects of the compound on the skin. This compound (1) can be obtained by culturing actinomycetes according to the above-mentioned document.
【0011】かかる化合物(1)は本発明皮膚化粧料中
に0.00001〜10重量%(以下単に%で示す)、
特に0.0001〜5%配合するのが好ましい。The compound (1) is contained in the skin cosmetic of the present invention in an amount of 0.00001 to 10% by weight (hereinafter simply referred to as%),
It is particularly preferable to add 0.0001 to 5%.
【0012】更に、本発明の皮膚化粧料には、前記必須
成分の他、通常の化粧料、医薬部外品、医薬品等に用い
られる各種任意成分、例えば油剤、保湿剤、増粘剤、防
腐剤、乳化剤、顔料、粉体、pH調整剤、薬効成分、紫外
線吸収剤、抗酸化剤、香料等を適宜配合することができ
る。In addition to the above essential ingredients, the skin cosmetic of the present invention also contains various optional ingredients used in ordinary cosmetics, quasi drugs, pharmaceuticals, etc., such as oils, moisturizers, thickeners and antiseptics. Agents, emulsifiers, pigments, powders, pH adjusters, medicinal components, ultraviolet absorbers, antioxidants, fragrances and the like can be appropriately added.
【0013】具体的には、油剤としては流動パラフィ
ン、ワセリン、パラフィンワックス、スクワラン、ミツ
ロウ、カルナウバロウ、オリーブ油、ラノリン、高級ア
ルコール、脂肪酸、高級アルコールと脂肪酸の合成エス
テル油、シリコーン油等が挙げられ、保湿剤としてはソ
ルビトール、キシリトール、グリセリン、マルチトー
ル、プロピレングリコール、ピロリドンカルボン酸ナト
リウム、ポリオキシプロピレン脂肪酸エステル、ポリエ
チレングリコール等が挙げられ、増粘剤としてはカルボ
キシビニルポリマー、カルボキシメチルセルロース、ポ
リビニルアルコール、カラギーナン、ゼラチン等の水溶
性高分子、塩化ナトリウム、塩化カリウム等の電解質な
どが挙げられ、防腐剤としてはメチルパラベン、エチル
パラベン、プロピルパラベン、ブチルパラベン、安息香
酸ナトリウム等が挙げられ、乳化剤としてはポリオキシ
エチレンアルキルエーテル、ポリオキシエチレン脂肪酸
エステル、ポリオキシエチレンソルビタン脂肪酸エステ
ル、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸
エステル、ポリオキシエチレングリセリン脂肪酸エステ
ル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチ
レンソルビトール脂肪酸エステル等の非イオン界面活性
剤が挙げられ、粉体としてはタルク、セリサイト、マイ
カ、カオリン、シリカ、ベントナイト、バーミキュライ
ト、亜鉛華、雲母、雲母チタン、酸化チタン、酸化マグ
ネシウム、酸化ジルコニウム、硫酸バリウム、ベンガ
ラ、酸化鉄、群青等が挙げられ、pH調整剤としてはクエ
ン酸−クエン酸ナトリウム等の緩衝剤が挙げられ、薬効
成分としては、アルブチン、コウジ酸、ビタミンC及び
その誘導体、プラセンタエキス、グリチルリチン酸ジカ
リウム、アラントイン、ビタミンE誘導体、パンテティ
ン酸誘導体、ヨクイニン、各種植物抽出物等が挙げられ
る。Specific examples of the oil agent include liquid paraffin, petrolatum, paraffin wax, squalane, beeswax, carnauba wax, olive oil, lanolin, higher alcohols, fatty acids, synthetic ester oils of higher alcohols and fatty acids, silicone oils, and the like. Examples of moisturizers include sorbitol, xylitol, glycerin, maltitol, propylene glycol, sodium pyrrolidonecarboxylate, polyoxypropylene fatty acid ester, polyethylene glycol, and the like, and thickeners include carboxyvinyl polymer, carboxymethylcellulose, polyvinyl alcohol, carrageenan. , Water-soluble polymers such as gelatin, and electrolytes such as sodium chloride and potassium chloride. Preservatives include methylparaben, ethylparaben, propylpa Ben, butyl paraben, sodium benzoate and the like can be mentioned. As the emulsifier, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester. , Nonionic surfactants such as polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitol fatty acid ester, etc., powders such as talc, sericite, mica, kaolin, silica, bentonite, vermiculite, zinc white, mica, mica. Examples include titanium, titanium oxide, magnesium oxide, zirconium oxide, barium sulfate, red iron oxide, iron oxide, ultramarine blue, and the like, and examples of pH adjusters include buffering agents such as citric acid-sodium citrate. Examples of the medicinal component include arbutin, kojic acid, vitamin C and its derivatives, placenta extract, dipotassium glycyrrhizinate, allantoin, vitamin E derivative, pantethenic acid derivative, yoquinin, and various plant extracts.
【0014】本発明の皮膚化粧料は常法に従って製造す
ることができる。また、本発明の対象となる皮膚化粧料
は、一般皮膚化粧料に限定されるものではなく、医薬部
外品、外用医薬品等を包含するものであり、その剤型も
クリーム、乳液、化粧水、ファンデーション、パック、
ローション状、ゲル状、溶液状、スティック状等、その
目的に応じて任意に選択することができる。The skin cosmetic of the present invention can be manufactured by a conventional method. Further, the skin cosmetics to be the subject of the present invention are not limited to general skin cosmetics, but include quasi drugs, external medicines, and the like, and their dosage forms are creams, emulsions, and lotions. , Foundation, pack,
A lotion form, a gel form, a solution form, a stick form, etc. can be arbitrarily selected according to the purpose.
【0015】[0015]
【作用及び発明の効果】化合物(1)はメラノサイトに
おけるメラニン生成を抑制し、かつ紫外線等の刺激によ
り生成したメラニン色素沈着を消退せしめる作用を有
し、これを配合した化粧料は優れた美白効果と、日焼け
等によるシミ及びソバカスの予防及び治療効果を有し、
かつ安全性も高いものである。ACTION AND EFFECTS OF THE INVENTION The compound (1) has an action of suppressing melanin production in melanocytes and of eliminating melanin pigmentation produced by stimulation with ultraviolet rays and the like, and cosmetics containing it have an excellent whitening effect. And has a preventive and therapeutic effect on spots and freckles due to sunburn, etc.,
It is also highly safe.
【0016】[0016]
【実施例】以下に本発明を実施例により具体的に説明す
るが、本発明はこれらによって限定されるものではな
い。EXAMPLES The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto.
【0017】実施例1(培養ヒトメラノサイトのメラニ
ン産生に対する効果) 正常ヒトメラノサイトの培養プレートに各濃度の試料を
添加し細胞のメラニン産生に対する効果を検討した。 (試験方法)クラボウ社より市販されている正常ヒトメ
ラノサイト(商品名メラノパック)を常法に従って継代
培養し本試験に供した。この細胞培養プレートに最終濃
度が0.00001〜100μMとなるように試料を添
加したのち一定期間後のメラノサイトのメラニン産生に
対する効果を調べた。なお、メラニン産生に対する効果
は、放射性チオウラシルの細胞内への取り込み量を定量
すること及び細胞を回収し、細胞ペレットの色調を肉眼
判定し、1〜4までの評価点をつけることにより行っ
た。色調の判定は、表1の判定基準により行った。評価
は、培養プレート10枚の評価点の平均で示した。Example 1 (Effect of Cultured Human Melanocytes on Melanin Production) Samples of various concentrations were added to a culture plate of normal human melanocytes to examine the effect on cell melanin production. (Test method) Normal human melanocytes (trade name: melanopack) marketed by Kurabo Industries were subcultured according to a conventional method and subjected to the present test. A sample was added to this cell culture plate so that the final concentration was 0.00001 to 100 μM, and the effect of melanocytes on melanin production after a certain period was examined. The effect on melanin production was performed by quantifying the amount of radioactive thiouracil incorporated into cells, collecting the cells, visually observing the color tone of the cell pellet, and assigning evaluation points of 1 to 4. The color tone was judged according to the judgment criteria shown in Table 1. The evaluation was shown by the average of the evaluation points of 10 culture plates.
【0018】[0018]
【表1】 [Table 1]
【0019】(結果)図1及び図2に示すように放射性
チオウラシルの細胞内への取り込みは0.001μM以
上の試料(化合物−a:R1=H,R2=OH、化合物−
b:R1=OCH3,R2=H)の添加により未処理に比
して有意にその取り込みの抑制が認められた。更に、表
2に示すように細胞ペレットの色調の肉眼判定では、5
μMあるいは10μMの濃度で明らかな細胞の白色化が
認められた。以上の結果から、イソフラボン誘導体
(1)の培養ヒトメラニン産生細胞のメラニン産生に対
する抑制効果が認められた。(Results) As shown in FIGS. 1 and 2, the incorporation of radioactive thiouracil into the cells was 0.001 μM or more (compound-a: R 1 = H, R 2 = OH, compound-
b: R 1 = OCH 3 , R 2 = H) was found to significantly inhibit the incorporation thereof as compared with the untreated sample. Furthermore, as shown in Table 2, the color of the cell pellet was visually judged to be 5
Clear whitening of cells was observed at a concentration of μM or 10 μM. From the above results, it was confirmed that the isoflavone derivative (1) has an inhibitory effect on the melanin production of cultured human melanin-producing cells.
【0020】[0020]
【表2】 [Table 2]
【0021】 実施例2(UVB色素斑に対する消退効果) 褐色モルモット20匹の背部毛をバリカンとシェーバー
にて丁寧に剃毛したのち、UVB領域の紫外線を最小紅
斑量(MED)の2倍量を1日1回3日間にわたり照射
し、誘導した色素斑に1日2回、1カ月間被験部位に評
価試験を連続塗布することによる色素斑消退量を調べ
た。試料としてはイソフラボン誘導体(1)を1%含有
する80%エタノール溶液を用い、コントロールとして
は溶媒(80%エタノール)のみを用いた。評価は、色
差計により測定を行い、得られたマンセル値からL*値
を算出し、試料塗布部位のΔL*(経時変化)から試料
未塗布(溶媒のみ=コントロール)部位のΔL*(経時
変化)を差し引いた値(ΔΔL*)により行った。な
お、ΔΔL*は以下の式にて表記される。 ΔΔL*=(L* 1−L* 0)−(L′* 1−L′* 0) L* 0 ;塗布前の試料塗布被験部位 L′* 0;塗布前の試料未塗布被験部位 L* 1 ;連続塗布1カ月後の試料塗布被験部位 L′* 1;連続塗布1カ月後の試料未塗布被験部位 評価は被験動物20匹の評価点の平均値(表3)で示し
た。Example 2 (Extinction Effect on UVB Pigment Spots) [0021] The back hair of 20 brown guinea pigs was carefully shaved with a clipper and a shaver, and then UV rays in the UVB region were doubled in an amount equal to the minimum erythema dose (MED). Irradiation was performed once a day for 3 days, and the amount of pigment spot elimination was examined by continuously applying the evaluation test to the test site twice a day for one month for the induced pigment spots. An 80% ethanol solution containing 1% of the isoflavone derivative (1) was used as a sample, and only a solvent (80% ethanol) was used as a control. Evaluation was measured by a color difference meter, obtained were calculated L * value from Munsell values, from the sample application site [Delta] L * (aging) samples uncoated (solvent only = control) site of [Delta] L * (aging ) Was subtracted (ΔΔL * ). Note that ΔΔL * is expressed by the following formula. ΔΔL * = (L * 1- L * 0 )-(L ' * 1- L' * 0 ) L * 0 ; sample-applied test site before application L ' * 0 ; sample-unapplied test site before application L * 1 ; Sample-applied test site after 1 month of continuous application L ' * 1 ; Sample-unapplied test site after 1 month of continuous application The evaluation was shown as the average value of the evaluation points of 20 test animals (Table 3).
【0022】[0022]
【表3】 [Table 3]
【0023】その結果、表4に示す如く、イソフラボン
誘導体(1)を含有する組成物にはコントロールに比し
て明らかな色素斑の消退作用が認められた。As a result, as shown in Table 4, the composition containing the isoflavone derivative (1) was found to have a clear pigment spot elimination effect as compared with the control.
【0024】[0024]
【表4】 [Table 4]
【0025】[0025]
【表5】 実施例2(クリーム) (組成) (%) (1)モノステアリン酸グリセリン 5.0 (2)モノステアリン酸ポリエチレングリコール 2.0 (3)スクワラン 8.0 (4)ステアリルアルコール 5.0 (5)トリオクタン酸グリセリル 8.0 (6)ジメチルポリシロキサン(50cs) 0.5 (7)グリセリン 5.0 (8)クエン酸 0.5 (9)クエン酸ナトリウム 0.5 (10)化合物−a 1.0 (11)6−アミノ−n−カプロン酸 0.5 (12)精製水 残量 (13)防腐剤 適量 (14)香料 適量Table 5 Example 2 (Cream) (Composition) (%) (1) Glycerin monostearate 5.0 (2) Polyethylene glycol monostearate 2.0 (3) Squalane 8.0 (4) Stearyl alcohol 5 0.0 (5) Glyceryl trioctanoate 8.0 (6) Dimethylpolysiloxane (50cs) 0.5 (7) Glycerin 5.0 (8) Citric acid 0.5 (9) Sodium citrate 0.5 (10) Compound-a 1.0 (11) 6-amino-n-caproic acid 0.5 (12) Purified water Remaining amount (13) Preservative proper amount (14) Perfume proper amount
【0026】[0026]
【表6】 実施例3(エッセンス) (組成) (%) (1)1,3−ブチレングリコール 8.0 (2)グリセリン 4.0 (3)キサンタンガム 0.3 (4)コンドロイチン硫酸ナトリウム 0.1 (5)ヒアルロン酸ナトリウム 0.1 (6)エタノール 3.0 (7)ポリオキシエチレンポリオキシプロピレンデシル テトラデシルエーテル 0.5 (8)化合物−b 0.5 (9)グリシン 0.5 (10)精製水 残量 (11)防腐剤 適量 (12)香料 適量Table 6 Example 3 (Essence) (Composition) (%) (1) 1,3-butylene glycol 8.0 (2) Glycerin 4.0 (3) Xanthan gum 0.3 (4) Sodium chondroitin sulfate 0.0. 1 (5) Sodium hyaluronate 0.1 (6) Ethanol 3.0 (7) Polyoxyethylene polyoxypropylene decyl tetradecyl ether 0.5 (8) Compound-b 0.5 (9) Glycine 0.5 ( 10) Purified water Remaining amount (11) Preservative Suitable amount (12) Perfume Suitable amount
【0027】[0027]
【表7】 実施例4(乳液) (組成) (%) (1)トリステアリン酸ポリオキシエチレンソルビタン 1.0 (2)オレイン酸グリセリル 1.0 (3)モノステアリン酸グリセリル 0.5 (4)スクワラン 6.0 (5)トリオクタン酸グリセリル 2.0 (6)オクタン酸セチル 2.0 (7)ステアリルアルコール 2.0 (8)メトキシケイ皮酸オクチル 2.0 (9)1,3−ブチレングリコール 5.0 (10)グリセリン 3.0 (11)化合物−a 0.1 (12)ニコチン酸アミド 1.0 (13)精製水 残量 (14)防腐剤 適量 (15)香料 適量Table 4 Example 4 (Emulsion) (Composition) (%) (1) Polyoxyethylenesorbitan tristearate 1.0 (2) Glyceryl oleate 1.0 (3) Glyceryl monostearate 0.5 (4 ) Squalane 6.0 (5) Glyceryl trioctanoate 2.0 (6) Cetyl octanoate 2.0 (7) Stearyl alcohol 2.0 (8) Octyl methoxycinnamate 2.0 (9) 1,3-butylene Glycol 5.0 (10) Glycerin 3.0 (11) Compound-a 0.1 (12) Nicotinic acid amide 1.0 (13) Purified water residual amount (14) Preservative proper amount (15) Perfume proper amount
【0028】[0028]
【表8】 実施例5(化粧水) (組成) (%) (1)1,3−ブチレングリコール 6.0 (2)グリセリン 4.0 (3)ヒアルロン酸ナトリウム 0.1 (4)エタノール 5.0 (5)ポリオキシエチレン−オレイルエーテル(20E.O.) 0.3 (6)エデト酸二ナトリウム 0.1 (7)クエン酸ナトリウム 1.0 (8)化合物−b 0.03 (9)塩化アンモニウム 0.5 (10)L−アスコルビン酸リン酸エステルマグネシウム 3.0 (11)精製水 残量 (12)防腐剤 適量 (13)香料 適量Table 8 Example 5 (Toilet lotion) (Composition) (%) (1) 1,3-butylene glycol 6.0 (2) Glycerin 4.0 (3) Sodium hyaluronate 0.1 (4) Ethanol 5 0.0 (5) Polyoxyethylene-oleyl ether (20 E.O.) 0.3 (6) Disodium edetate 0.1 (7) Sodium citrate 1.0 (8) Compound-b 0.03 (9 ) Ammonium chloride 0.5 (10) L-ascorbic acid phosphoric acid ester magnesium 3.0 (11) Purified water Remaining amount (12) Preservative proper amount (13) Perfume proper amount
【0029】[0029]
【表9】 実施例6(クリーム状ファンデーション) (組成) (%) (1)ジメチルポリシロキサン(6cs) 10.0 (2)メチルフェニルポリシロキサン 3.0 (3)オクタメチルシクロテトラシロキサン 10.0 (4)ポリオキシアルキレン変性シリコーン 5.0 (5)酸化チタン 5.0 (6)セリサイト 2.0 (7)タルク 3.0 (8)ベンガラ 0.4 (9)酸化鉄黄 0.7 (10)酸化鉄黒 0.1 (11)グリセリン 5.0 (12)化合物−a 0.05 (13)6−アミノ−n−カプロン酸 0.5 (14)精製水 残量 (15)防腐剤 適量 (16)香料 適量Table 9 Example 6 (Cream foundation) (Composition) (%) (1) Dimethylpolysiloxane (6cs) 10.0 (2) Methylphenylpolysiloxane 3.0 (3) Octamethylcyclotetrasiloxane 10. 0 (4) polyoxyalkylene-modified silicone 5.0 (5) titanium oxide 5.0 (6) sericite 2.0 (7) talc 3.0 (8) red iron oxide 0.4 (9) iron oxide yellow 7 (10) Iron oxide black 0.1 (11) Glycerin 5.0 (12) Compound-a 0.05 (13) 6-Amino-n-caproic acid 0.5 (14) Purified water balance (15) Preservative Suitable amount (16) Perfume Suitable amount
【0030】[0030]
【表10】 実施例7(パック) (組成) (%) (1)ジプロピレングリコール 3.0 (2)ポリエチレングリコール 3.0 (3)1,3−ブチレングリコール 1.0 (4)グリセリン 2.0 (5)ピロリドンカルボン酸ナトリウム 1.0 (6)化合物−b 0.05 (7)乳酸 0.5 (8)乳酸ナトリウム 0.5 (9)ポリビニルアルコール 12.0 (10)エタノール 3.0 (11)ポリオキシエチレンポリオキシプロピレンデシル テトラデシルエーテル 0.3 (12)精製水 残量 (13)防腐剤 適量 (14)香料 適量Table 10 Example 7 (pack) (composition) (%) (1) dipropylene glycol 3.0 (2) polyethylene glycol 3.0 (3) 1,3-butylene glycol 1.0 (4) glycerin 2 0.0 (5) Sodium pyrrolidonecarboxylate 1.0 (6) Compound-b 0.05 (7) Lactic acid 0.5 (8) Sodium lactate 0.5 (9) Polyvinyl alcohol 12.0 (10) Ethanol 3. 0 (11) Polyoxyethylene polyoxypropylene decyl tetradecyl ether 0.3 (12) Purified water remaining amount (13) Preservative appropriate amount (14) Perfume appropriate amount
【図1】化合物−aの放射性チオウラシルの細胞内への
取り込みに及ぼす作用を示す図である。FIG. 1 is a diagram showing the effect of compound-a on the intracellular uptake of radioactive thiouracil.
【図2】化合物−bの放射性チオウラシルの細胞内への
取り込みに及ぼす作用を示す図である。FIG. 2 is a diagram showing the effect of compound-b on the intracellular uptake of radioactive thiouracil.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/35 ADS 9454−4C ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display area A61K 31/35 ADS 9454-4C
Claims (2)
原子又は水酸基を示す〕で表わされるイソフラボン誘導
体からなる美白剤。1. The following general formula (1): A whitening agent comprising an isoflavone derivative represented by the formula: wherein R 1 represents a hydrogen atom or a methoxy group, and R 2 represents a hydrogen atom or a hydroxyl group.
有する皮膚化粧料。2. A skin cosmetic containing the isoflavone derivative according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10672793A JPH06321752A (en) | 1993-05-07 | 1993-05-07 | Skin beautifying agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10672793A JPH06321752A (en) | 1993-05-07 | 1993-05-07 | Skin beautifying agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06321752A true JPH06321752A (en) | 1994-11-22 |
Family
ID=14440975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10672793A Pending JPH06321752A (en) | 1993-05-07 | 1993-05-07 | Skin beautifying agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH06321752A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0998262A4 (en) * | 1997-06-11 | 2000-05-10 | Sherwood L Gorbach | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
US6093411A (en) * | 1998-03-16 | 2000-07-25 | The Procter & Gamble Company | Compositions for regulating skin appearance |
WO2000049009A1 (en) * | 1999-02-15 | 2000-08-24 | Novogen Research Pty. Ltd. | Production of isoflavone derivatives |
EP1205179A1 (en) * | 2000-11-10 | 2002-05-15 | L'oreal | Cosmetic composition comprising an aminophenol derivative and an isoflavonoid |
JP2002542187A (en) * | 1999-04-16 | 2002-12-10 | アストラゼネカ・アクチエボラーグ | Estrogen-β receptor ligand |
JP2003002819A (en) * | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
JP2005170910A (en) * | 2003-12-15 | 2005-06-30 | Kuraray Co Ltd | Skin preparation |
US6987098B2 (en) | 1992-05-19 | 2006-01-17 | Novogen Research Pty. Ltd. | Health supplement |
US7033621B1 (en) | 1997-04-28 | 2006-04-25 | Novogen, Inc. | Isoflavone compositions produced from legumes |
US7202273B2 (en) | 1996-08-30 | 2007-04-10 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
CN100400534C (en) * | 2003-07-10 | 2008-07-09 | 华北制药集团有限责任公司 | Aldose reductase inhibitor, its preparation method and use |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
CN106166119A (en) * | 2015-05-21 | 2016-11-30 | 佐登妮丝国际股份有限公司 | Use of 3' -hydroxygenistein for preparing composition for inhibiting melanin generation |
TWI718389B (en) * | 2018-07-04 | 2021-02-11 | 佐登妮絲國際股份有限公司 | Use of 3'-hydroxygenistein for anti-photoaging |
-
1993
- 1993-05-07 JP JP10672793A patent/JPH06321752A/en active Pending
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045155B2 (en) | 1992-05-19 | 2006-05-16 | Novogen Research Pty Ltd. | Dietary supplements comprising soy hypocotyls containing at least one isoflavone |
US6987098B2 (en) | 1992-05-19 | 2006-01-17 | Novogen Research Pty. Ltd. | Health supplement |
US7202273B2 (en) | 1996-08-30 | 2007-04-10 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
US7033621B1 (en) | 1997-04-28 | 2006-04-25 | Novogen, Inc. | Isoflavone compositions produced from legumes |
EP0998262A1 (en) * | 1997-06-11 | 2000-05-10 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
EP0998262A4 (en) * | 1997-06-11 | 2000-05-10 | Sherwood L Gorbach | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
US6093411A (en) * | 1998-03-16 | 2000-07-25 | The Procter & Gamble Company | Compositions for regulating skin appearance |
WO2000049009A1 (en) * | 1999-02-15 | 2000-08-24 | Novogen Research Pty. Ltd. | Production of isoflavone derivatives |
JP2002542187A (en) * | 1999-04-16 | 2002-12-10 | アストラゼネカ・アクチエボラーグ | Estrogen-β receptor ligand |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
EP1205179A1 (en) * | 2000-11-10 | 2002-05-15 | L'oreal | Cosmetic composition comprising an aminophenol derivative and an isoflavonoid |
FR2816502A1 (en) * | 2000-11-10 | 2002-05-17 | Oreal | COSMETIC COMPOSITION CONSISTING OF AN AMINOPHENOL DERIVATIVE AND AN ISOFLAVONOIDE |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
JP2003002819A (en) * | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
CN100400534C (en) * | 2003-07-10 | 2008-07-09 | 华北制药集团有限责任公司 | Aldose reductase inhibitor, its preparation method and use |
JP2005170910A (en) * | 2003-12-15 | 2005-06-30 | Kuraray Co Ltd | Skin preparation |
CN106166119A (en) * | 2015-05-21 | 2016-11-30 | 佐登妮丝国际股份有限公司 | Use of 3' -hydroxygenistein for preparing composition for inhibiting melanin generation |
TWI718389B (en) * | 2018-07-04 | 2021-02-11 | 佐登妮絲國際股份有限公司 | Use of 3'-hydroxygenistein for anti-photoaging |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06321752A (en) | Skin beautifying agent | |
JP2764510B2 (en) | Whitening cosmetics | |
JP2534191B2 (en) | Whitening agent | |
JP2001002558A (en) | Bleaching cosmetic | |
JPH06321764A (en) | Skin beautifying agent | |
JPH1121226A (en) | Skin preparation for external use for suppressing melanin production | |
JPH0761919A (en) | Bautifying agent | |
JPH06312920A (en) | Skin-beautifying agent and skin cosmetic containing the agent | |
JPH06312919A (en) | Skin-beautifying agent and skin cosmetic containing the agent | |
JPH06321759A (en) | Skin beautifying agent | |
JP3447791B2 (en) | Whitening agent | |
JPH06321765A (en) | Skin beautifying agent | |
JPH06172150A (en) | Skin cosmetic | |
JPH06321758A (en) | Skin beautifying agent | |
JPH06321751A (en) | Skin beautifying agent | |
JPH06321753A (en) | Skin beautifying agent | |
JPH08333232A (en) | Whitening agent | |
JPH06321763A (en) | Skin beautifying agent | |
JPH06321749A (en) | Whitening agent | |
JPH06321756A (en) | Skin beautifying agent | |
JPH08283114A (en) | Skin lightener | |
JPH06321757A (en) | Skin beautifying agent | |
JPH06321750A (en) | Skin beautifying agent | |
JPH0952817A (en) | Beautifying and whitening cosmetic | |
JPH06321747A (en) | Dermal medicine for external use |